Monz takes over as ceo of Carl Zeiss Meditec

Ludwin Monz has been named as chief executive of Carl Zeiss Meditec.

Ludwin Monz has been named as chief executive of Carl Zeiss Meditec. He takes over from Michael Kaschke, who resumes his role as chairman of the company's supervisory board.

Monz has been a member of Carl Zeiss Meditec's management board since October 2007 and is responsible for the firm's Ophthalmological Systems division. Prior to this he led the Microsurgery division for six years.

With a doctorate in physics and an MBA, Monz joined the Carl Zeiss Group in 1994 and has worked in medical technology since 2000.

You may also like

Digital

Why CGT manufacturers should automate the production process

Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
Manufacturing

TrakCel to support cell and gene therapy orchestration with OCELLOS IT solution

The IT system allows cell and gene therapy (CGT) manufacturers to track the progress of personalised CGTs in real-time, while also managing their supply chain
Manufacturing

Asymchem fully automates its therapeutic peptide manufacturing processes

The company has facilitated the scale-up of its peptide manufacturing capabilities, with its production capacity now standing at 10,000 L
Manufacturing

How AI can optimise your pharmaceutical manufacturing processes and raise throughput

Artificial intelligence (AI) allows pharmaceutical manufacturers to perform predictive maintenance, which can reduce downtime and enhance process efficiency
Digital

How AI and GenAI will revolutionise the healthcare industry

Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and interact with one another
Research & Development

Xybion launches AI-enabled LIMS technology, LIMS 10.0

The laboratory information management system (LIMS) can improve a lab's functionality and efficiency for users across a vast range of industries
Digital

AI in pharma: the trends and future of the tech in the industry

AI can enhance the efficiency and cost-effectiveness of a range of processes across the pharmaceutical industry, so S&P Global explores the current scope of the tech and its future potential
Subscribe now